Loading cancer entity…
Loading cancer entity…
Clinical trials
181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (27)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04054245 | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01901432 | A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera | completed | Phase 1 / Phase 2 | 48 | ItalfarmacoINDUSTRY | 5 | Jul 30, 2019 | clinicaltrials |
| NCT00946270 | Pomalidomide for Myelofibrosis Patients | completed | Phase 2 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2019 | clinicaltrials |
| NCT02311569 | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | completed | Phase 2 | 39 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT02421354 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT00509899 | Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis | completed | Phase 1 / Phase 2 | 154 | Incyte CorporationINDUSTRY | 1 | Mar 12, 2018 | clinicaltrials |
| NCT01193699 | Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera(PEGINVERA) | completed | Phase 1 / Phase 2 | 24 | AOP Orphan Pharmaceuticals AGINDUSTRY | 1 | Jan 30, 2018 | clinicaltrials |
| NCT00538980 | Dasatinib in Polycythemia Vera | terminated | Phase 2 | 10 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01243073 | Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera(ET/PV) | completed | Phase 2 | 20 | Geron CorporationINDUSTRY | 3 | Jan 26, 2016 | clinicaltrials |
| NCT00241241 | Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera | completed | Phase 2 | 40 | PV-NordOTHER | 1 | Oct 21, 2015 | clinicaltrials |
| NCT00586651 | Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis | completed | Phase 2 | 39 | CephalonINDUSTRY | 1 | Oct 8, 2015 | clinicaltrials |
| NCT01298934 | LBH589 (Panobinostat) for the Treatment of Myelofibrosis | unknown | Phase 1 / Phase 2 | 22 | Ronald HoffmanOTHER | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00381550 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2015 | clinicaltrials |
| NCT00668421 | CEP-701 (Lestaurtinib) in Myelofibrosis | unknown | Phase 1 / Phase 2 | 60 | Ronald HoffmanOTHER | 1 | Nov 26, 2014 | clinicaltrials |
| NCT00940784 | Clopidogrel and Aspirin for the Treatment of Polycythemia Vera(ISCLAP) | withdrawn | Phase 2 | 0 | Ronald HoffmanOTHER | 0 | Nov 26, 2014 | clinicaltrials |
| NCT00430066 | Effects of Imatinib Mesylate in Polycythemia Vera | completed | Phase 2 | 9 | Niguarda HospitalOTHER | 0 | Oct 8, 2014 | clinicaltrials |
| NCT00227591 | Lenalidomide and Prednisone in Treating Patients With Myelofibrosis | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00039416 | Imatinib Mesylate in Treating Patients With Myelofibrosis | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2014 | clinicaltrials |
| NCT00047190 | Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00745550 | A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis | completed | Phase 1 / Phase 2 | 55 | S*BIOINDUSTRY | 2 | Apr 20, 2012 | clinicaltrials |
| NCT00866762 | A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia | unknown | Phase 2 | 60 | Copenhagen University Hospital at HerlevOTHER | 4 | Dec 12, 2011 | clinicaltrials |
| NCT01120821 | Treatment of Polycythemia Vera With Gleevec | completed | Phase 2 | 36 | Weill Medical College of Cornell UniversityOTHER | 1 | May 17, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Aug 13, 2019source: clinicaltrials